Journal
BRITISH JOURNAL OF CANCER
Volume 91, Issue 8, Pages 1420-1424Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6602162
Keywords
PI3K pathway; PTEN; Akt; m-TOR; CCI-779; rapamycin
Categories
Ask authors/readers for more resources
mTOR is a downstream mediator in the PI3K/Akt signalling pathway, which plays a critical role in regulating basic cellular functions. These include cell proliferation, survival, mobility and angiogenesis. Rapamycin and its analogues (CCl-779, RAD001 and AP23573) have specific antagonistic action on the function of mTOR. This leads to inhibition of the downstream signalling elements and results in the cell cycle arrest in the G1 phase. This group of drugs may have a place in Oncology for the treatment of cancers, which occur as a result of increased activity of the PI3 kinase/Akt/m-TOR pathway. The basic structure of the pathway was reviewed in this article, together with results of the clinical studies targeting mTOR for cancer therapy. This is an exciting area for development and poses many challenges to researchers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available